Lien vers Pubmed [PMID] – 21073307
Future Microbiol 2010 Oct;5(10):1469-73
The Ebola and Marburg viruses (from the filovirus family) induce deadly hemorrhagic fevers for which there is currently no licensed vaccine or treatment. Frequent outbreaks have occurred in sub-Saharan Africa, in humans and nonhuman primates over the last 15 years or so and constitute a major public health problem. Of particular concern, a new species of Ebolavirus recently emerged in Uganda, highlighting the high potential of these viruses to evolve and the need to develop ‘broad-spectrum’ vaccines against filoviruses. Hensley et al. used their well studied vaccine platform based on DNA vectors and recombinant, replication-defective, adenoviruses producing Ebolavirus glycoproteins to protect cynomolgus monkeys against a heterologous challenge with the new species. Further developments are required before this experimental approach could be adapted for field use in humans, but this study nevertheless constitutes a proof-of-concept for broad protection against Ebolaviruses.